Related Experiment Video
Updated: Jan 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser
Kamini Raghuram1, Maram Isaac2, Junmin Yang3
1Division of Neonatology, Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
Insights
Intravitreal bevacizumab (IVB) showed no significant differences in neurodevelopmental impairment (NDI) compared to laser ablation in preterm infants. Further research is needed to confirm the long-term safety and efficacy of IVB in neonates.
Area of Science:
- Neonatal ophthalmology
- Developmental pediatrics
Background:
- Retinopathy of prematurity (ROP) is a leading cause of visual impairment in preterm infants.
- Intravitreal bevacizumab (IVB) and laser ablation are common treatments for ROP.
- Long-term neurodevelopmental and visual outcomes following these treatments require further investigation.
Purpose of the Study:
- To compare neurodevelopmental and visual outcomes in preterm infants treated with IVB versus laser ablation.
- To assess neurodevelopmental impairment (NDI) and significant NDI (sNDI) at 18-24 months corrected age.
- To evaluate structural and refractive visual outcomes.
Main Methods:
- Retrospective study comparing 34 infants (60 eyes) treated with IVB and 30 infants (51 eyes) treated with laser.
- Primary outcome: NDI. Secondary outcomes: sNDI, cerebral palsy, hearing loss, Bayley Scales of Infant Development III scores, and visual outcomes.
- Statistical analysis included adjusted odds ratios (AOR) controlling for gestational age, sex, and ROP severity.
Main Results:
- No significant differences were found in NDI (AOR 1.77) or sNDI (AOR 2.31) between the IVB and laser groups.
- No other significant differences in neurodevelopmental or visual outcomes were observed.
- The study included infants treated for retinopathy of prematurity.
Conclusions:
- Current evidence suggests comparable neurodevelopmental and visual outcomes between IVB and laser treatment for ROP in preterm infants at 18-24 months corrected age.
- Larger randomized trials are necessary to definitively establish the long-term efficacy and safety of IVB in this population.
- IVB may be a viable alternative to laser ablation, but further research is warranted.
Objective:
To compare neurodevelopmental and visual outcomes in preterm infants treated with intravitreal bevacizumab (IVB) to laser ablation at 18-24 months corrected age.
Study Design:
A retrospective study was performed. The primary outcome was neurodevelopmental impairment (NDI). Secondary neurodevelopmental outcomes were significant NDI (sNDI), cerebral palsy, hearing loss, and composite scores of the Bayley Scales of Infant Development, Third edition. Visual outcomes included structural and refractive outcomes. Adjusted odds ratios (AOR) were calculated controlling for GA, sex, and ROP severity and confounding baseline characteristics using a cutoff of p < 0.20.
Results:
Thirty-four (60 eyes) infants receiving IVB and 30 (51 eyes) laser were included. No significant differences were identified in NDI (AOR 1.77, 95% CI 0.46, 6.73) or sNDI (AOR 2.31, 95% CI 0.75, 7.14). There were no other differences in outcomes.
Conclusions:
Larger randomized trials are required to establish long-term efficacy and safety of IVB in preterm neonates.
Related Concept Videos
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Drug Dosing: Infants and Children
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Matrix-Assisted Laser Desorption Ionization (MALDI)

